Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- UK: Comments wanted on phytosterol
French company, DRT, has asked for a decision on its phytosterol ingredient, which is derived from tall oil pitch – a substance distilled from pine resin.
- UK: Comments wanted on phytosterol
French company, DRT, has asked for a decision on its phytosterol ingredient, which is derived from tall oil pitch – a substance distilled from pine resin.
- UK: Comments wanted on phytosterol
French company, DRT, has asked for a decision on its phytosterol ingredient, which is derived from tall oil pitch – a substance distilled from pine resin.
- TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products
Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia.
- TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products
Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia.
- TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products
Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia.
- TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products
Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia.
- TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products
Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia.
- Cargill Expands GRAS Status of Oliggo-Fiber® Inulin and Oligofructose Products
Company has expanded the GRAS (Generally Recognized As Safe) status of its Oliggo-Fiber® brand of inulin and oligofructose products through an independent evaluation by a qualified scientific expert, permitting the Oliggo-Fiber inulin and oligofructose line of products for general use in foods at levels consistent with current good manufacturing practice.
- Cargill Expands GRAS Status of Oliggo-Fiber® Inulin and Oligofructose Products
Company has expanded the GRAS (Generally Recognized As Safe) status of its Oliggo-Fiber® brand of inulin and oligofructose products through an independent evaluation by a qualified scientific expert, permitting the Oliggo-Fiber inulin and oligofructose line of products for general use in foods at levels consistent with current good manufacturing practice.
- Cargill Expands GRAS Status of Oliggo-Fiber® Inulin and Oligofructose Products
Company has expanded the GRAS (Generally Recognized As Safe) status of its Oliggo-Fiber® brand of inulin and oligofructose products through an independent evaluation by a qualified scientific expert, permitting the Oliggo-Fiber inulin and oligofructose line of products for general use in foods at levels consistent with current good manufacturing practice.
- Cargill Expands GRAS Status of Oliggo-Fiber® Inulin and Oligofructose Products
Company has expanded the GRAS (Generally Recognized As Safe) status of its Oliggo-Fiber® brand of inulin and oligofructose products through an independent evaluation by a qualified scientific expert, permitting the Oliggo-Fiber inulin and oligofructose line of products for general use in foods at levels consistent with current good manufacturing practice.
- Hi-Fil® Lutein Achieves GRAS Status
Hi-Fil® Lutein products, manufactured by Industrial Organica and distributed exclusively by Pharmline Inc., has attained self-affirmed GRAS (Generally Recognized As Safe) status, through an independent evaluation by an expert panel of scientists.
- Hi-Fil® Lutein Achieves GRAS Status
Hi-Fil® Lutein products, manufactured by Industrial Organica and distributed exclusively by Pharmline Inc., has attained self-affirmed GRAS (Generally Recognized As Safe) status, through an independent evaluation by an expert panel of scientists.
- Hi-Fil® Lutein Achieves GRAS Status
Hi-Fil® Lutein products, manufactured by Industrial Organica and distributed exclusively by Pharmline Inc., has attained self-affirmed GRAS (Generally Recognized As Safe) status, through an independent evaluation by an expert panel of scientists.
- Hi-Fil® Lutein Achieves GRAS Status
Hi-Fil® Lutein products, manufactured by Industrial Organica and distributed exclusively by Pharmline Inc., has attained self-affirmed GRAS (Generally Recognized As Safe) status, through an independent evaluation by an expert panel of scientists.
- Sabinsa Secures Approval From Government of India to Use Its Ocufors(TM) Eye Drop Solution for Glaucoma Treatment
Company has been granted permission by the Drugs Controller General of India to manufacture and market Ocufors(TM), an ophthalmic solution containing one percent forskolin, for the treatment of glaucoma.
- Sabinsa Secures Approval From Government of India to Use Its Ocufors(TM) Eye Drop Solution for Glaucoma Treatment
Company has been granted permission by the Drugs Controller General of India to manufacture and market Ocufors(TM), an ophthalmic solution containing one percent forskolin, for the treatment of glaucoma.
- Sabinsa Secures Approval From Government of India to Use Its Ocufors(TM) Eye Drop Solution for Glaucoma Treatment
Company has been granted permission by the Drugs Controller General of India to manufacture and market Ocufors(TM), an ophthalmic solution containing one percent forskolin, for the treatment of glaucoma.
- Sabinsa Secures Approval From Government of India to Use Its Ocufors(TM) Eye Drop Solution for Glaucoma Treatment
Company has been granted permission by the Drugs Controller General of India to manufacture and market Ocufors(TM), an ophthalmic solution containing one percent forskolin, for the treatment of glaucoma.
- GRAS Status Affirmed for Lipogen Phosphatidylserine
Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line.
- GRAS Status Affirmed for Lipogen Phosphatidylserine
Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line.
- GRAS Status Affirmed for Lipogen Phosphatidylserine
Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line.
- GRAS Status Affirmed for Lipogen Phosphatidylserine
Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line.
- NSF International Awards First GMP for Sport(TM) Registration to Century Foods International
NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program.
- NSF International Awards First GMP for Sport(TM) Registration to Century Foods International
NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program.
- NSF International Awards First GMP for Sport(TM) Registration to Century Foods International
NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program.
- NSF International Awards First GMP for Sport(TM) Registration to Century Foods International
NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program.
- NSF International Awards First GMP for Sport(TM) Registration to Century Foods International
NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program.
- NSF International Awards First GMP for Sport(TM) Registration to Century Foods International
NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program.
- FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims
At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act.
- FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims
At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act.
- FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims
At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act.
- FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims
At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act.
- FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims
At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act.
- Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP
Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application.
- Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP
Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application.
- Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP
Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application.
- Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP
Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application.
- Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP
Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application.
- Ontario Government Closer to Regulating Traditional Chinese Medicine
Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading.
- Ontario Government Closer to Regulating Traditional Chinese Medicine
Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading.
- Ontario Government Closer to Regulating Traditional Chinese Medicine
Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading.
- FDA Authorizes Qualified Health Claim for Canola Oil
The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states:
Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil.
- FDA Authorizes Qualified Health Claim for Canola Oil
The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states:
Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil.
- FDA Authorizes Qualified Health Claim for Canola Oil
The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states:
Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil.
- FDA Authorizes Qualified Health Claim for Canola Oil
The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states:
Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil.
- FDA Authorizes Qualified Health Claim for Canola Oil
The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states:
Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil.
- FDA Authorizes Qualified Health Claim for Canola Oil
The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states:
Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil.
- Allimax Nutraceuticals US starts clinical trial for treating Lyme disease
Allimax Nutraceuticals US, in conjunction with the Health Healing and Hope Foundation, have started their Lyme disease double blind clinical study being conducted in Texas by Dr.’s Joan Vandergriff ND, Hamid Moayad DO, William Keller Ph.D., Hugo Rodier M.D.
- Allimax Nutraceuticals US starts clinical trial for treating Lyme disease
Allimax Nutraceuticals US, in conjunction with the Health Healing and Hope Foundation, have started their Lyme disease double blind clinical study being conducted in Texas by Dr.’s Joan Vandergriff ND, Hamid Moayad DO, William Keller Ph.D., Hugo Rodier M.D.
- Health Canada Issues 'Approach to the Refusal of Product license Applications'
Health Canada has issued a notice regarding its approach to the refusal of Product License Applications. The approach is posted at http://www.hc-sc.gc.ca/dhp-mps/prodnatur/bulletins/pl-ref-lp_e.html.
- Health Canada Issues 'Approach to the Refusal of Product license Applications'
Health Canada has issued a notice regarding its approach to the refusal of Product License Applications. The approach is posted at http://www.hc-sc.gc.ca/dhp-mps/prodnatur/bulletins/pl-ref-lp_e.html.
- Health Canada Issues 'Approach to the Refusal of Product license Applications'
Health Canada has issued a notice regarding its approach to the refusal of Product License Applications. The approach is posted at http://www.hc-sc.gc.ca/dhp-mps/prodnatur/bulletins/pl-ref-lp_e.html.
- Health Canada Approves Second Martek DHA For Food Uses
Company announces that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods.
- Health Canada Approves Second Martek DHA For Food Uses
Company announces that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods.
- Health Canada Approves Second Martek DHA For Food Uses
Company announces that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods.
- Health Canada Approves Second Martek DHA For Food Uses
Company announces that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods.
- Health Canada Approves Second Martek DHA For Food Uses
Company announces that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods.
- Health Canada Approves Second Martek DHA For Food Uses
Company announces that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods.
- Indian Food Safety and Standards Bill 2005 signed into law.
GCI Nutrients-India reports that the Indian Food Safety and Standards Bill 2005 was recently signed into law by the President of India.
- Indian Food Safety and Standards Bill 2005 signed into law.
GCI Nutrients-India reports that the Indian Food Safety and Standards Bill 2005 was recently signed into law by the President of India.
- NHPD October 2006 Monthly Communiqué Available
The NHPD Monthly Communiqué, October 2006 (Vol. 2, Issue 2), is now available online.
- NHPD October 2006 Monthly Communiqué Available
The NHPD Monthly Communiqué, October 2006 (Vol. 2, Issue 2), is now available online.
- NHPD October 2006 Monthly Communiqué Available
The NHPD Monthly Communiqué, October 2006 (Vol. 2, Issue 2), is now available online.
- Talks Ongoing: Trans-Tasman regulatory scheme
A second phase of consultation on the proposed trans-Tasman regulatory scheme for therapeutic products is now underway and feedback is being invited.
- Talks Ongoing: Trans-Tasman regulatory scheme
A second phase of consultation on the proposed trans-Tasman regulatory scheme for therapeutic products is now underway and feedback is being invited.
- United Natural Products Alliance (UNPA) Statement On The Status of Federal Dietary Supplement Serious Adverse Event Reporting Legislation
UNPA will continue to work aggressively for passage of the Non-Prescription Drug and Dietary Supplement Consumer Protection Act (S.3546/H.R.6168) when the Congress reconvenes for a brief “lame duck” session the week after the November elections.
- United Natural Products Alliance (UNPA) Statement On The Status of Federal Dietary Supplement Serious Adverse Event Reporting Legislation
UNPA will continue to work aggressively for passage of the Non-Prescription Drug and Dietary Supplement Consumer Protection Act (S.3546/H.R.6168) when the Congress reconvenes for a brief “lame duck” session the week after the November elections.
- United Natural Products Alliance (UNPA) Statement On The Status of Federal Dietary Supplement Serious Adverse Event Reporting Legislation
UNPA will continue to work aggressively for passage of the Non-Prescription Drug and Dietary Supplement Consumer Protection Act (S.3546/H.R.6168) when the Congress reconvenes for a brief “lame duck” session the week after the November elections.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
Defendants Allegedly Sold Millions Of Pills Over The Internet
ATLANTA – Eleven individuals and an Atlanta-based company have been indicted by a federal grand jury on multiple felony charges relating to a scheme to sell adulterated and unapproved new drugs over the internet. Four of the defendants were scheduled to appear at a bond hearing before United States Magistrate Linda Walker at 1:45 p.m. today.
In a news conference, DEA Special Agent In Charge Sherri Strange said, “One of the fastest growing drug abuse concerns is prescription drugs. The selling and purchasing of drugs have been facilitated by the wide use of the internet, the anonymity it provides, and the ease and relative secrecy of the mail and private delivery companies. A recent search engine query for ‘prescription drugs for sale online’ resulted in over 10 million hits. President Bush, Attorney General Gonzales, and DEA Administrator Tandy have made prescription drug abuse a priority for DEA. As our children sit down at the family computer to do their schoolwork, research projects, and converse with friends, criminal organizations like the one alleged today slither into their lives. Every one of us has received spam e-mails directing us to visit websites to order supposed generic prescription drugs and controlled substances. Buyers beware. I am proud that DEA works closely with the FDA, other federal agencies, and foreign counterparts to thwart such criminal organizations.”
United States Attorney David E. Nahmias said, “The indictment’s allegations are disturbing because customers thought they were getting legitimate and safe prescription drugs over the internet from Canada at cheaper prices, when in reality they received adulterated fakes that were crudely made in an unsanitary house in Belize.”
FDA Office of Criminal Investigations Special Agent In Charge David Bourne said, “The FDA’s Office of Criminal Investigations actively pursues those who deceive the public by manufacturing and selling unapproved and unregulated medications which may pose risks to the health of consumers. We are committed to investigating and preventing those who use trickery and deceit to illegally and unscrupulously sell medications over the internet at the expense of the public health."
The defendants named in the indictment are: JARED ROBERT WHEAT, 34, of Alpharetta, Georgia; DAVID DALTON JOHNSON, 37, of Pinehurst, North Carolina; DAVID ALAN BRADY, 40, of Pinehurst, North Carolina; STEPHEN DOUGLAS SMITH, 38, of Duluth, Georgia; THOMAS HOLDA, 43, of Duluth, Georgia; SERGIO RONALDO OLIVEIRA, 46, of Hoschton, Georgia; BRAD NEAL WATKINS, 38, of Birmingham, Alabama; DAVID WATKINS, 40, of Norcross, Georgia; STEVEN BLINDER, 42, of Aberdeen, South Dakota; MICHELLE YOUNG, 38, a citizen of Belize; and, GUILLERMO PECH, 28, also a citizen of Belize; and HI-TECH PHARMACEUTICALS, a company based in Norcross, Georgia.
All of the defendants are charged with two different conspiracies: (1) conspiring to import controlled substances into the United States; and (2) conspiring to violate the wire and mail fraud statute and to introduce into interstate commerce adulterated and misbranded prescription drugs. The indictment charges each of the defendants, except DAVID WATKINS, BRAD WATKINS and STEVEN BLINDER, with different substantive violations including mail fraud, distribution of controlled substances and introducing adulterated and misbranded new drugs. The indictment also charges the lead defendant, JARED WHEAT, with engaging in a continuing criminal enterprise. The indictment seeks to forfeit numerous properties, automobiles and bank accounts, and seeks a money judgment of not less than $19.8 million.
According to United States Attorney Nahmias, the indictment, search warrants and other information presented in court: WHEAT, the principal owner of Hi-Tech Pharmaceuticals, and the other defendants opened a drug manufacturing facility in Belize in approximately 2002. The defendants allegedly used Hi-Tech funds and JARED WHEAT’s own funds to cover the costs of operating the Hi-Tech facility in Belize and would travel to Belize to manufacture various prescription and controlled substances. The defendants allegedly made approximately 24 different drugs that they marketed through so-called “spam” advertisements over the internet as authentic generic versions of those drugs being imported from Canada. The drugs included steroids such as “Oxymethelone” and “Stanazolol,” along with unapproved versions of controlled drugs such as “Ambien,” “Valium,” and “Xanax.” The defendants also manufactured versions of prescription drugs such as “Viagra,” “Cialis,” “Lipitor” and “Vioxx.” From 2002 through 2004, the defendants allegedly ordered enough active ingredients to manufacture millions of pills, many of which were then shipped into the United States to individuals who purchased the drugs after receiving internet “spam” and also to various wholesalers of drugs.
Members of the public are reminded that the indictment only contains charges. The defendants are presumed innocent of the charges and it will be the government's burden to prove each defendant's guilt beyond a reasonable doubt at trial.
The U.S. Attorney's Office in Atlanta recommends parents and children learn about the dangers of drugs at the following web site: www.justthinktwice.com.
This case is being investigated by Special Agents of the DEA and the Food and Drug Administration, Office of Criminal Investigations, with the Henry County Police Department. Valuable assistance has been provided by the Bureau of Alcohol, Tobacco and Firearms (ATF), the Customs and Border Protection Foreign Mail Facility in Miami, the Postal Inspection Service, Doraville Police Department, Roswell Police Department, City of Atlanta Police Department, Spalding County Sheriff's Office, Cobb County Sheriff's Office, Clarkston Police Department, East Point Police Department and the Duluth Police Department.
Assistant United States Attorneys Aaron M. Danzig, Randy S. Chartash and J. Russell Phillips are prosecuting the case.
For further information please contact David E. Nahmias (pronounced NAH-me-us), United States Attorney, or Charysse L. Alexander, Executive Assistant United States Attorney, through Patrick Crosby, Public Affairs Officer, U.S. Attorney's Office, at (404) 581-6016. The Internet address for the HomePage for the U.S. Attorney's Office for the Northern District of Georgia is www.usdoj.gov/usao/gan.
|